Copy/Paste the key inputs from the product brochure, per guidance from Marketing.
The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and two IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics in AxSpA patients refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and the growing IL-17 class, which has efficacy data that have met more-stringent clinical trial endpoints. Cimzia was approved by the FDA in 2019 for nonradiographic (nr)-AxSpA, marking the first FDA approval for that subpopulation, followed by Cosentyx and Taltz in June 2020. The impending entry of additional IL-17 inhibitors (UCB’s bimekizumab and Kyowa Hakko Kirin’s Lumicef) and the first oral targeted therapy–Jak inhibitors–for this indication (Pfizer’s Xeljanz and AbbVie's Rinvoq) will also shift market dynamics.
- How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
- What are interviewed experts’ insights on current treatment options for ankylosing spondylitis (AS) and nr-AxSpA? What clinical needs remain unfulfilled?
- What pipeline products are the most promising, and what sales / uptake could they secure in AxSpA? What therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the AxSpA market, and how will the market evolve over the forecast period?
Geographies: United States, EU5, Japan
Primary Research: ~30 country-specific interviews with thought-leading rheumatologists; Supported by survey data collected for this and other DRG research
Epidemiology: Diagnosed prevalent cases of axial spondyloarthritis by country, ankylosing spondylitis and nonradiographic axial spondyloarthritis subpopulations
Forecast: 10-year, annualized, drug-level sales and patient share of key axial spondyloarthritis therapies through 2028, segmented by brands/generics and epidemiological subpopulations
Emerging therapies: Phase III/PR: 4 drugs; Phase II: 2 drugs
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Axial Spondyloarthritis - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Qinghui Yu, PhD; Mudasir Khan, M.P.H.
Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases.
Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science industries. Qinghui Yu holds a Ph.D. in Neuroscience from Columbia University.
Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.
Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.